MDPI and ACS Style
Bauman, J.E.; Julian, R.; Saba, N.F.; Wise-Draper, T.M.; Adkins, D.R.; O’Brien, P.; Fidler, M.J.; Gibson, M.K.; Duvvuri, U.; Heath-Chiozzi, M.;
et al. Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers 2022, 14, 2355.
https://doi.org/10.3390/cancers14102355
AMA Style
Bauman JE, Julian R, Saba NF, Wise-Draper TM, Adkins DR, O’Brien P, Fidler MJ, Gibson MK, Duvvuri U, Heath-Chiozzi M,
et al. Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers. 2022; 14(10):2355.
https://doi.org/10.3390/cancers14102355
Chicago/Turabian Style
Bauman, Julie E., Ricklie Julian, Nabil F. Saba, Trisha M. Wise-Draper, Douglas R. Adkins, Paul O’Brien, Mary Jo Fidler, Michael K. Gibson, Umamaheswar Duvvuri, Margo Heath-Chiozzi,
and et al. 2022. "Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer" Cancers 14, no. 10: 2355.
https://doi.org/10.3390/cancers14102355